Literature DB >> 11064386

Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma.

H Shinchi1, S Takao, H Nishida, T Aikou.   

Abstract

BACKGROUND AND OBJECTIVES: Hilar cholangiocarcinoma is a morbid disease with a poor prognosis because resection cannot be performed in many cases. The purpose of this study was to evaluate whether external beam radiotherapy (RT) combined with expandable metallic biliary stent (EMS) affects the length and quality of survival of patients with unresectable hilar cholangiocarcinomas.
METHODS: Fifty-one patients with unresectable hilar cholangiocarcinoma were retrospectively reviewed. Thirty patients received external beam radiotherapy combined with EMS (EMS+RT group), 10 patients were treated with EMS alone (EMS group), and the remaining 11 patients underwent percutaneous transhepatic biliary drainage alone (PTBD group). The length and quality of survival were analyzed and compared among the three groups.
RESULTS: The mean survival of 6.4 months in the EMS group was significantly longer than that of 4.4 months in the PTBD group (P < 0.05). The EMS+RT group with a mean survival of 10.6 months had a significantly longer survival than the EMS group (P < 0.05). The average of the monthly Karnofsky scores of 74.9 in the EMS+RT group and 68.1 in the EMS group, as a parameter of quality of survival, was significantly higher than that of 57.7 in the PTBD group (P < 0.01). The number of hospital days per month of survival was significantly smaller in the EMS+RT and EMS groups than in the PTBD group (10.4, 14.2 vs. 27.3 days; P < 0.001). The EMS+RT group had a longer stent patency than the EMS group (mean: 9.8 vs. 3.7 months; P < 0.001).
CONCLUSIONS: These results indicate that external radiotherapy combined with metallic biliary endoprosthesis can increase the length and quality of survival and consequently provide a definite palliative benefit for patients with unresectable hilar cholangiocarcinoma. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 11064386     DOI: 10.1002/1096-9098(200010)75:2<89::aid-jso3>3.0.co;2-v

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  14 in total

1.  Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM.

Authors:  Zhi-Hua Liu; Yan-Ping He; Yukun Zhou; Peng Zhang; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2010-01-29       Impact factor: 2.316

2.  Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome.

Authors:  S D Mansfield; O Barakat; R M Charnley; B C Jaques; C B O'Suilleabhain; P J Atherton; D Manas
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Feasibility of biodegradable PLGA common bile duct stents: an in vitro and in vivo study.

Authors:  Xiaoyi Xu; Tongjun Liu; Shaohui Liu; Kai Zhang; Zhen Shen; Yuxin Li; Xiabin Jing
Journal:  J Mater Sci Mater Med       Date:  2009-01-09       Impact factor: 3.896

Review 4.  Endoscopic management of hilar cholangiocarcinoma.

Authors:  Andrea Parodi; Deborah Fisher; Marc Giovannini; Todd Baron; Massimo Conio
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-24       Impact factor: 46.802

5.  Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.

Authors:  A Paiman Ghafoori; John W Nelson; Christopher G Willett; Junzo Chino; Douglas S Tyler; Herbert I Hurwitz; Hope E Uronis; Michael A Morse; Robert W Clough; Brian G Czito
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-23       Impact factor: 7.038

Review 6.  Palliation: Hilar cholangiocarcinoma.

Authors:  Mahesh Kr Goenka; Usha Goenka
Journal:  World J Hepatol       Date:  2014-08-27

7.  Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma.

Authors:  Yong Tan; Jian-Yong Zhu; Bao-An Qiu; Nian-Xin Xia; Jing-Han Wang
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

8.  Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma.

Authors:  Aaron J Quyn; Dorin Ziyaie; Francesco M Polignano; Iain S Tait
Journal:  HPB (Oxford)       Date:  2009-11       Impact factor: 3.647

9.  The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939.

Authors:  Zhi-Hua Liu; Yan-Ping He; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2009-09-13       Impact factor: 2.316

Review 10.  Palliation of malignant obstructive jaundice.

Authors:  G Garcea; S L Ong; A R Dennison; D P Berry; G J Maddern
Journal:  Dig Dis Sci       Date:  2008-09-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.